In melt granulation for oral solid dosage forms, hard fat is metered into a jacketed twin-screw extruder as a melt binder at 5–20% w/w of the dry powder blend. The barrel temperature is maintained 5–10°C above the slip melting point of the selected Adeps solidus grade, typically 40–50°C for a material with a 33°C melting onset. Gravimetric feeders are calibrated to ±1% feed accuracy to prevent localized binder-rich zones. Screw speed in production-scale equipment ranges from 150–300 rpm; this corresponds to residence times of 30–90 seconds depending on barrel L/D ratio, usually between 20:1 and 40:1. The molten binder wets lactose, mannitol, dibasic calcium phosphate, or microcrystalline cellulose; wetted agglomerates exit the barrel and are cooled on a vibratory conveyor with 10–15°C purge air. Rapid cooling traps hard fat in the low-melting α crystalline form. If cooling is too slow, brittle β crystals form and subsequent tablets can show lamination. After 12–24 hours at 20–25°C, partial conversion from α to β′ hardens the granules from bulk density 0.45–0.60 g/mL to the upper end of that range while maintaining a Carr index of 12–18%. Polymorph identity is monitored by differential scanning calorimetry at 5°C/min according to ASTM D3418-21. Compression on a rotary press with precompression force 10–15 kN and main compression force 20–30 kN produces tablets with a target hardness of 60–120 N for a 10 mm diameter round tooling set. Content uniformity of the final tablets is verified according to USP <905>. Dissolution testing in 0.1 N HCl at 37°C using USP apparatus 2 at 50 rpm shows release rates controlled by pore formation and lipid erosion. Hard-fat-bound matrices are sensitive to storage temperature; above 30°C polymorph conversion accelerates and release slows. Tablets should be packed in moisture barriers because sorbed water above 60% RH can plasticize the lipid and change porosity. This configuration is not suitable for APIs requiring rapid release in the fasted stomach unless a disintegrant such as crospovidone at 5–10% w/w is incorporated, because the hydrophobic lipid phase can extend disintegration time beyond 15 minutes in USP <701> testing. The process is appropriate for moisture-sensitive APIs, but process hold times above 45°C should be limited to avoid degradation of triglyceride ester bonds and free fatty acid formation.

The compendial profile that supports these operations is summarized in the following matrix.

Why Does Hot-Melt Coating Demand a Narrow Product Bed Temperature Window?

A bottom-spray Wurster fluidized-bed coater is used to apply hard fat onto granules or pellets at a coating level of 5–15% w/w. The melt is prepared at 40–45°C and delivered through a heated twin-fluid nozzle. Atomizing air pressure is held between 1.5 and 2.5 bar; lower values generate droplets that wet insufficiently, while higher values create fine mist that solidifies before impact. Product bed temperature is maintained at 18–22°C for a hard fat with slip melting point of 33°C because the droplets must spread on the substrate and then crystallize within seconds. Inlet air temperature is set to 15–25°C, and the dew point is controlled below 8°C to avoid moisture condensation on the cooling surface. If bed temperature drops below 15°C, the lipid solidifies too early and coating thickness becomes uneven. If bed temperature exceeds 25°C, the coated particles become tacky and defluidization occurs; this is the principal process failure observed on pilot lines. The partition gap in the Wurster insert is set to 10–30 mm depending on substrate median particle size. Coating efficiency, defined as the mass fraction of hard fat retained on the substrate relative to the delivered melt, is typically reported at 80–92% for optimized runs; published data for this specific configuration is limited. Release measurement in pH 6.8 phosphate buffer with USP apparatus 2 at 50 rpm can monitor taste-masking performance for bitter APIs. Hard fat alone forms a brittle film; addition of glyceryl monostearate at 10–20% of the lipid phase improves film elasticity and reduces cracking during fluidization. Residual solvent concerns are minimal because the process is solvent-free; compliance with ICH Q3C is therefore based only on raw material residuals. Aqueous film coating is generally unsuitable for hard fat surfaces because the required inlet temperature can soften the lipid layer; if a pH-sensitive overcoat is required, the bed temperature must remain below 25°C and the overcoat must be applied in a separate operation before lipid crystallization has fully completed.

Hard gelatin capsules can be filled with a molten lipid matrix containing hard fat at 10–25% w/w of the fill mass. The fill is maintained at 35–40°C in a jacketed vessel and dosed by a positive-displacement pump into size 0 or size 00 capsules; the nozzles are heated to avoid premature solidification. After filling, the capsules pass through a cooling tunnel at 15–20°C for 10–20 minutes to set the matrix into a semi-solid state. Hard fat functions as a thixotropic structuring agent: under shear in the pump and nozzle, the molten fill viscosity drops, allowing accurate dosing; once static in the cooled capsule, the matrix regains structure and prevents sedimentation of suspended drug. Moisture content of the fill is controlled below 0.5% because free water migrates to the gelatin shell and causes brittleness. The fill temperature must not exceed 45°C because higher temperatures can denature gelatin shells; for HPMC capsules, the upper fill temperature can be 5–10°C higher, but cooling time increases. Release from these matrices is governed by erosion and diffusion in 0.1 N HCl with pepsin using USP apparatus 2 at 50 rpm; formulation-specific erosion rates must be established for each drug load because no single release time applies. Higher hard fat levels produce brittle matrices that fracture during transport, causing dose dumping; lower levels allow capsule leakage during handling at 30°C. Capsule sealing via banding is required because molten lipid can wick between the cap and body and reduce closure integrity. The system is appropriate for low-dose, moisture-sensitive APIs, but not for highly hydrophilic drugs with poor lipid solubility; such drugs partition into aqueous pores and release too slowly. Inspections use visual checks and weight sorting with a rejection limit of ±2% of target fill mass. Stability protocols follow ICH Q1A at 25°C/60% RH and 40°C/75% RH; weight loss, shell cracking, and lipid matrix firmness are evaluated at each pull point. In-process monitoring follows 21 CFR 211.110 to document fill weight, temperature, and cooling tunnel residence time.

When Hard Fat Is Blended with High-Melting Lipids for Injectable Depot Matrices

Injectable delivery of hard fat requires formulation design that shifts the melting range above physiological temperature. Unmodified Adeps solidus melts at 32–36°C; a depot injected intramuscularly or subcutaneously at 37°C would remain soft and could coalesce. The lipid phase is therefore blended with glyceryl dibehenate or fully hydrogenated soybean oil so that the final matrix has a melting endotherm above 39°C by DSC. Molten lipid and drug solution or micronized drug suspension are emulsified using a rotor-stator homogenizer at 10,000–20,000 rpm, then passed through a high-pressure homogenizer at 500–1,000 bar for 3–5 cycles to form solid lipid microparticles. Particle size is measured by laser diffraction according to ISO 13320-1:2020; for intramuscular suspensions, a median diameter of 5–50 µm is common, whereas intravenous administration is not applicable because particles in this range exceed the 5 µm capillary safety threshold. Lipid emulsions intended for intravenous use must meet USP <729> globule size distribution limits; hard fat-based microparticles are not suitable for that route without extensive size reduction and terminal sterilization validation. Sterilization is a critical operational boundary: moist heat at 121°C for 15 minutes can melt the lipid and alter particle size distribution, while gamma irradiation at 25 kGy may increase peroxide value above 5 meq O2/kg and require re-qualification. Terminal sterilization is therefore evaluated case-by-case; aseptic processing is often required, with sterility testing per USP <71> and endotoxin limits per USP <85>. In vitro release from solid lipid microparticles is tested in pH 7.4 phosphate-buffered saline with 0.5% polysorbate 80 using a USP apparatus 4 flow-through cell at 35 mL/min; this method avoids sticking of lipid particles to USP apparatus 1/2 vessels. Hard fat contributes matrix erosion but not a stable solid depot by itself. Published data for injectable hard fat depots are limited compared with oral solid dosage forms; formulation-specific polymorphism, particle size, and sterility studies are required before a production batch is released.

Direct Compression Lubrication and Ejection Force Reduction in Low-Dose Tablet Presses

Hard fat in powder form is used as a hydrophobic lubricant in direct compression blends at 1–3% w/w, particularly for formulations where magnesium stearate causes incompatibility or dissolution slowdown. The material is sieved to a particle size below 100 µm; larger particulates create visible surface defects and variable lubrication. Mixing time in a tumble blender is set to 5–10 minutes at 10–25 rpm. Long blending times above 15 minutes can smear the lipid onto filler particles and reduce tablet disintegration. On a high-speed rotary press operating at 30–80 rpm, addition of hard fat at 2% w/w reduces ejection force by 20–35% relative to unlubricated blends in instrumented tablet presses; this range is derived from production-scale monitoring of ejection cams, though exact values depend on tooling condition and punch geometry. The lubricant does not require melting; frictional heat under compression can generate localized temperatures near 30–35°C, so press speeds above 100 rpm may soften hard fat and increase sticking. Tablet hardness is less affected than with magnesium stearate, but compression force must be increased by 5–10% to match target hardness because the lipid can reduce interparticulate bonding. Disintegration testing per USP <701> in water at 37°C shows a delay of 2–5 minutes at the 2% w/w level. The material is not suitable for effervescent tablets because the hydrophobic film retards water penetration and prolongs reaction. Hard fat lubrication is also limited in high-dose tablets where the lubricant level needed for adequate ejection force reduces compact strength below the release specification.